Ardelyx, Inc. (NASDAQ: ARDX) reported that it met the primary endpoint and seven of eight secondary endpoints in its Phase 3 T3MPO-1 trial of tenapanor for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). The data showed that a greater proportion of...
More